The cytokine levels and miRNA expression in patients with major depressive disorder and its modulation by silymarin

JIPMER Dhanvantari nagar Gorimedu Puducherry0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Newly diagnosed drug naÃ¯ve patients with the first episode of major depressive disorder as per DSM-5 criteria and additionally confirmed using M.I.N.I plus (Mini international neuropsychiatric interview) and HAM-D (Hamilton depression rating scale) score of > 13 (major depressive disorder).
•2.Participants with the age group of 18-65 years of either gender.

•1.H/O suspected organic or substance-induced mood disorder.
•2.H/O uncontrolled diabetes (HbA1c > 8), cancer, immunological disorders such as systemic lupus erythematosus, endocrinopathies such as hypothyroidism/hyperthyroidism.
•3.Patients who are on NSAIDs, steroids and other immune-modulatory therapies.
•4.Patients who are not willing to give consent
•5.H/O coronary artery disease, congestive heart failure and arrhythmias.
•6.H/O fever/ clinical evidence of active infections or wounds in the last 2 weeks.
•7.H/O surgery or burns in the last 1 month.
•8.H/O substance abuse.
•9.Patients with suicidal tendency, psychotic disorders, mania and hypomania.
•10.Pregnant women or lactating mother.
•11.Women in a reproductive age group not practicing adequate contraceptive measures.
•12.Patients who had participated in other trials in the past three months.
•13.Patients on herbal medications.

发起方

JIPMER Dhanvantari nagar Gorimedu Puducherry